FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2133582768> ?p ?o ?g. }

• W2133582768 endingPage "83" @default.
• W2133582768 startingPage "75" @default.
• W2133582768 abstract "This was a multinational, multicentre, double-blind Phase II study in Europe to evaluate the efficacy and safety of two dose regimens (200 mg bid and 200 mg tid) of sarpogrelate (MCI-9042, 5-HT 2A receptor antagonist) compared to placebo in patients with stable, moderately severe intermittent claudication. Following a single-blind placebo run-in period of 6 weeks, 364 (309 male and 55 female) patients (59.2 ± 8.4 years, mean SD) were randomized to receive sarpogrelate 200 mg bid, 200 mg tid or placebo for 24 weeks with a follow-up of 8 weeks. The primary objective was the increase of absolute claudication distance (ACD) at the end of treatment (week 24) compared to placebo. Analysis of covariance (ANCOVA) was performed on the log-transformed percentage of baseline ACD: log e (ACD/baseline). A responder analysis (defined as a 50% improvement in ACD) was also performed. There was a marked training/placebo effect on the ACD which persisted up to 16 weeks. At 24 weeks the primary objective did not reach statistical significance (200 mg bid vs placebo, p = 0.225; 200 mg tid vs placebo, p = 0.580). In the responder analysis, 200 mg bid showed a statistically significant difference vs placebo ( p = 0.035). In the exploratory analysis with completers (patients completing all treadmill tests), there was a statistical difference in ACD/baseline change for 200 mg bid ( p = 0.035) and in the responder analysis for 200 mg tid ( p = 0.044) at 24 weeks compared to placebo. Both treatments showed a carry-over effect for ACD during the 8-week follow-up (weeks 28-32). The treatment was well tolerated and no clinically significant safety concerns were reported. In conclusion, the study results confirm that sarpogrelate is well tolerated and although the primary endpoint failed to reach statistical significance, the responder analysis showed an increased absolute walking distance, which makes a further trial warranted, including a larger population, and possibly also a longer treatment period." @default.
• W2133582768 created "2016-06-24" @default.
• W2133582768 creator A5036565067 @default.
• W2133582768 creator A5038722538 @default.
• W2133582768 creator A5044774843 @default.
• W2133582768 creator A5054249775 @default.
• W2133582768 creator A5090500019 @default.
• W2133582768 date "2006-05-01" @default.
• W2133582768 modified "2023-09-23" @default.
• W2133582768 title "Sarpogrelate, a 5-HT2A receptor antagonist in intermittent claudication. A Phase II European study" @default.
• W2133582768 cites W1491380749 @default.
• W2133582768 cites W1855557460 @default.
• W2133582768 cites W1973498254 @default.
• W2133582768 cites W1988269241 @default.
• W2133582768 cites W1988357107 @default.
• W2133582768 cites W1990172683 @default.
• W2133582768 cites W1993278665 @default.
• W2133582768 cites W2003321530 @default.
• W2133582768 cites W2015442311 @default.
• W2133582768 cites W2025251707 @default.
• W2133582768 cites W2052395633 @default.
• W2133582768 cites W2057244473 @default.
• W2133582768 cites W2065573482 @default.
• W2133582768 cites W2070488805 @default.
• W2133582768 cites W2093019635 @default.
• W2133582768 cites W2140343720 @default.
• W2133582768 cites W2150144608 @default.
• W2133582768 cites W2159740443 @default.
• W2133582768 cites W2329086250 @default.
• W2133582768 cites W2399597808 @default.
• W2133582768 cites W2529311275 @default.
• W2133582768 cites W4242618726 @default.
• W2133582768 cites W4256353558 @default.
• W2133582768 doi "https://doi.org/10.1191/1358863x06vm657oa" @default.
• W2133582768 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16886837" @default.
• W2133582768 hasPublicationYear "2006" @default.
• W2133582768 type Work @default.
• W2133582768 sameAs 2133582768 @default.
• W2133582768 citedByCount "30" @default.
• W2133582768 countsByYear W21335827682012 @default.
• W2133582768 countsByYear W21335827682013 @default.
• W2133582768 countsByYear W21335827682014 @default.
• W2133582768 countsByYear W21335827682015 @default.
• W2133582768 countsByYear W21335827682016 @default.
• W2133582768 countsByYear W21335827682017 @default.
• W2133582768 countsByYear W21335827682019 @default.
• W2133582768 countsByYear W21335827682021 @default.
• W2133582768 countsByYear W21335827682023 @default.
• W2133582768 crossrefType "journal-article" @default.
• W2133582768 hasAuthorship W2133582768A5036565067 @default.
• W2133582768 hasAuthorship W2133582768A5038722538 @default.
• W2133582768 hasAuthorship W2133582768A5044774843 @default.
• W2133582768 hasAuthorship W2133582768A5054249775 @default.
• W2133582768 hasAuthorship W2133582768A5090500019 @default.
• W2133582768 hasConcept C126322002 @default.
• W2133582768 hasConcept C142724271 @default.
• W2133582768 hasConcept C170493617 @default.
• W2133582768 hasConcept C204787440 @default.
• W2133582768 hasConcept C27081682 @default.
• W2133582768 hasConcept C2776885963 @default.
• W2133582768 hasConcept C2777466421 @default.
• W2133582768 hasConcept C2778963770 @default.
• W2133582768 hasConcept C2779881954 @default.
• W2133582768 hasConcept C3018348675 @default.
• W2133582768 hasConcept C42219234 @default.
• W2133582768 hasConcept C65409693 @default.
• W2133582768 hasConcept C71924100 @default.
• W2133582768 hasConceptScore W2133582768C126322002 @default.
• W2133582768 hasConceptScore W2133582768C142724271 @default.
• W2133582768 hasConceptScore W2133582768C170493617 @default.
• W2133582768 hasConceptScore W2133582768C204787440 @default.
• W2133582768 hasConceptScore W2133582768C27081682 @default.
• W2133582768 hasConceptScore W2133582768C2776885963 @default.
• W2133582768 hasConceptScore W2133582768C2777466421 @default.
• W2133582768 hasConceptScore W2133582768C2778963770 @default.
• W2133582768 hasConceptScore W2133582768C2779881954 @default.
• W2133582768 hasConceptScore W2133582768C3018348675 @default.
• W2133582768 hasConceptScore W2133582768C42219234 @default.
• W2133582768 hasConceptScore W2133582768C65409693 @default.
• W2133582768 hasConceptScore W2133582768C71924100 @default.
• W2133582768 hasIssue "2" @default.
• W2133582768 hasLocation W21335827681 @default.
• W2133582768 hasLocation W21335827682 @default.
• W2133582768 hasOpenAccess W2133582768 @default.
• W2133582768 hasPrimaryLocation W21335827681 @default.
• W2133582768 hasRelatedWork W1523446869 @default.
• W2133582768 hasRelatedWork W2011440291 @default.
• W2133582768 hasRelatedWork W2037941776 @default.
• W2133582768 hasRelatedWork W2080170034 @default.
• W2133582768 hasRelatedWork W2084177335 @default.
• W2133582768 hasRelatedWork W2085302846 @default.
• W2133582768 hasRelatedWork W2139755348 @default.
• W2133582768 hasRelatedWork W2465732382 @default.
• W2133582768 hasRelatedWork W4255036279 @default.
• W2133582768 hasRelatedWork W2405848351 @default.
• W2133582768 hasVolume "11" @default.
• W2133582768 isParatext "false" @default.
• W2133582768 isRetracted "false" @default.

• next